US Patent No: 4,824,660

Number of patents in Portfolio can not be more than 2000

Method of determining the viability of tissue in an organism

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A method of determining the viability of tissue in a region of an organism comprises the steps of introducing an ATP repleting agent into the region and monitoring the region to determine its effect on T1-201 distribution in the region. The capability of viable tissue to synthesize ATP and increase its ATP stores provides an indication of the viability of the tissue in the region. In a preferred embodiment of the method, ribose, which is a high energy phosphate precursor and an ATP repleting agent, is introduced into heart tissue that is being monitored by T1-201 scintigraphy. The ribose increases the rate and extent of T1-201 distribution in the heart tissue, thereby allowing the determination of viable "stunned" heart tissue. That viable tissue is distinguishable from nonviable tissue is attributed to the capability of the former to synthesize ATP and increase its ATP stores in response to the administration of the ATP repleting agent. Such manipulation of ATP stores in a region of tissue effects a detectable change in T1-201 distribution in that region. The method permits, therefore, the rapid determination of viable heart tissue.R

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ANGELLO; PAUL S.LAKE OSWEGO, OR1
ANGELLO, PAUL S., 1858 PALISADES TERRACE DRIVE, LAKE OSWEGO, OREGON 97034LAKE OSWEGO, OR1

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Angello, Debra A Charlottesville, VA 1 32
Wilson, Richard A Westfield, NJ 99 916

Cited Art

Patent Info (Count) # Cites Year
 
UNIVERSITY OF VIRGINIA (1)
4,364,922 Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances 23 1980

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
UNIVERSITY OF VIRGINIA (19)
6,117,878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors 52 1998
6,322,771 Induction of pharmacological stress with adenosine receptor agonists 34 1999
6,448,235 Method for treating restenosis with A2A adenosine receptor agonists 32 2000
6,514,949 Method compositions for treating the inflammatory response 32 2000
6,531,457 Methods and compositions for treating inflammatory response 25 2001
6,670,334 Method and compositions for treating the inflammatory response 24 2002
7,214,665 2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof 17 2002
7,226,913 Pharmaceutical compositions having A.sub.2A adenosine receptor agonist activity 9 2003
7,427,606 Method to reduce inflammatory response in transplanted tissue 11 2004
7,605,143 agonist activity 9 2005
7,576,069 2-polycyclic propynyl adenosine analogs having A2A agonist activity 8 2005
7,442,687 2-polycyclic propynyl adenosine analogs having A2A agonist activity 7 2005
7,378,400 Method to reduce an inflammatory response from arthritis 13 2005
8,178,509 Method to treat sickle cell disease 0 2007
7,737,127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 5 2007
8,188,063 modulators to treat spinal cord injury 0 2007
7,989,431 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity 3 2009
7,875,595 2-polycyclic propynyl adenosine analogs having A2A agonist activity 4 2009
8,158,604 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 0 2010
 
BIOENERGY, INC. (5)
6,339,716 Method for determining viability of a myocardial segment 4 1999
6,218,366 Method for raising the hypoxic threshold 6 1999
6,159,943 Use of ribose to prevent cramping and soreness in muscles 8 1999
6,703,370 Use of ribose to treat fibromyalgia 1 2000
8,101,581 Use of D-ribose to treat cardiac arrhythmias 6 2008
 
ADERIS PHARMACEUTICALS, INC. (3)
5,117,830 Method of determining viability of tissue 30 1990
5,256,398 Composition for determining viability of tissue 10 1992
5,477,857 Diagnostic uses of hydrazinoadenosines 8 1993
 
BIOENERGY LIFE SCIENCE, INC. (2)
6,159,942 Compositions for increasing energy in vivo 17 1999
6,534,480 Compositions for increasing energy in vivo 3 2000
 
PATENT FOUNDATION, VIRGINIA, UNIVERSITY OF (1)
6,232,297 Methods and compositions for treating inflammatory response 28 1999
 
PGXHEALTH, LLC (1)
8,058,259 R agonists 3 2008
 
SIEMENS MEDICAL SOLUTIONS USA, INC. (1)
6,015,384 Ultrasonic system and method for tissue viability imaging 18 1998